Congress recently passed short‑term PAMA relief, delaying rate cuts for one year and shifting the next private payer data‑collection period to January–July 2025, with reporting beginning May 2026. While helpful, long‑term reform is still needed, and momentum is growing behind the bipartisan RESULTS Act. In this on‑demand session, ACLA President Susan Van Meter and ACLA General Counsel Joyce Gresko explain what these changes mean for labs, with moderation by Tom Cronin, SVP at Quadax.

Reimbursement for molecular and genetic testing is more complex than ever. With shifting MolDx policies, evolving payer guidelines, and growing prior authorization requirements, laboratories must stay proactive to safeguard revenue and maintain compliance.

In this on-demand webinar, industry experts Ann Lambrix and Tara Cepull break down the latest payer expectations, upcoming regulatory changes, and actionable strategies to minimize denials and optimize reimbursement